Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Head & Neck 2CNS 1

Conditions

Sarcoma, Ewing 2Rhabdomyosarcoma 2Osteosarcoma 2Neuroblastoma 2Glioma 2Glioblastoma 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Sarcoma 1Rhabdoid Tumor 1Recurrence 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms 1Hepatoblastoma 1Gliosarcoma 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 23Bevacizumab 18Cyclophosphamide 9Carboplatin 7Lomustine 6Irinotecan 63-Iodobenzylguanidine 6Topotecan 5Radiotherapy 5Filgrastim 5Radiosurgery 4Nivolumab 4Everolimus 4Etoposide 4Busulfan 4sonidegib 3pembrolizumab 3olaparib 3fludarabine phosphate 3fludarabine 3antineoplaston AS 2-1 3antineoplaston A10 3Vincristine 3Thiotepa 3Sirolimus 3Melphalan 3IL13-PE38 3Drug Therapy 3Antilymphocyte Serum 3verubulin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × irinotecan sucrosofate × CNS × Clear all
NCT02013336 2022-03-31

Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

South Plains Oncology Consortium

Phase 1 Unknown
30 enrolled
CNSSarcoma

Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡